APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1:100-1:200 |
Note :
IHC-P
Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended.
|
Not tested in other applications.
Calculated MW
Positive Control
Capillary hemangioma, dermatofibroma, and placenta
PROPERTIES
Form
Liquid
Buffer
Tris-HCl, 0.2% BSA
Preservative
0.09% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC.
Concentration
Batch dependent (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Recombinant fragment of human Factor XIIIa protein
Purification
Purified IgG
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
coagulation factor XIII A chain , F13A
Cellular Localization
Cytoplasm , Secreted
Background
This gene encodes the coagulation factor XIII A subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. It also crosslinks alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion. [provided by RefSeq, Jul 2008]
Database
Research Area
REFERENCE
There are currently no references for Factor XIIIa antibody [ZM84] (GTX01688). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for Factor XIIIa antibody [ZM84] (GTX01688). Be the first to share your experience with this product.